Back to top
more

National Vision (EYE)

(Real Time Quote from BATS)

$12.17 USD

12.17
800,542

-0.18 (-1.46%)

Updated Jul 10, 2024 03:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (170 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

National Vision (EYE) Hits Fresh High: Is There Still Room to Run?

National Vision (EYE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Earnings Preview: National Vision (EYE) Q3 Earnings Expected to Decline

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why You Should Hold on to Walgreens Boots (WBA) for Now

Investors are optimistic about Walgreens Boots (WBA) given its better-than-expected fourth-quarter fiscal 2021 results and strategic alliances.

Here's Why You Should Hold on to Hill-Rom (HRC) for Now

Investors are optimistic about Hill-Rom (HRC) owing to strategic buyouts and continued expansion efforts in the digital health space.

3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now

Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.

Walgreens (WBA) to Make Additional Investment in VillageMD

Walgreens (WBA) announced a $5.2-billion investment in VillageMD to bolster its strategic position in delivering value-based primary care.

National Vision (EYE) Soars to 52-Week High, Time to Cash Out?

National Vision (EYE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Retain National Vision (EYE) For Now

Investors are optimistic about National Vision (EYE) owing to new store growth and pandemic-induced increase in demand for the company's offerings.

The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma

The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma

Riya Anand headshot

4 Stocks to Keep a Watch on Amid Growing Optical Care Demand

Stocks like Alcon (ALC), National Vision (EYE), The Cooper Companies (COO) and EyePoint Pharmaceuticals (EYPT) are gaining momentum amid rising optical care demand.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Company News for Aug 13, 2021

Companies In The News Are: CSIQ, DDS, EYE, AZEK

National Vision (EYE) Q2 Earnings Top Estimates, 2021 View Up

Strength in Americas Best and Eyeglass World brands drove National Vision's (EYE) revenues in the second quarter of 2021.

National Vision (EYE) Surpasses Q2 Earnings and Revenue Estimates

National Vision (EYE) delivered earnings and revenue surprises of 108.70% and 11.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

National Vision (EYE) to Report Q2 Earnings: What's in Store?

National Vision (EYE) is expected to report sequentially better results for the second quarter on gradual reopening of stores and return toward more normal operations.

National Vision (EYE) Earnings Expected to Grow: Should You Buy?

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

National Vision (EYE) Banks on Partnerships Amid COVID-19 Woes

National Vision (EYE) is confident about its financial flexibility and liquidity helping it to navigate this pandemic.

OPKO Health (OPK) Inks Licensing Deal for AntagoNAT Technology

OPKO Health's (OPK) latest licensing agreement is expected to advance the development and commercialization of potential disease-modifying therapeutics, especially for Dravet syndrome.

Inogen (INGN) Hits New 52-Week High: What's Driving It?

Investors are optimistic about Inogen's (INGN) direct-to-customer business model and a strong product portfolio.

QIAGEN (QGEN) Stock Falls on Downbeat Full-Year Guidance

According to QIAGEN (QGEN), stronger-than-expected growth trends were seen in non-COVID product groups in the second quarter of 2021.

NuVasive (NUVA) International Sales Solid Despite COVID-19 Woes

We are upbeat about NuVasive's (NUVA) newly-introduced organizational and leadership structure for its global commercial operations as well as its product and services organization.

Riya Anand headshot

3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19

Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.

Medtronic (MDT) Reports Economic Findings on PRODIGY Data

Medtronic (MDT)-sponsored PRODIGY Trial data was used to analyze cost benefits and outcomes from continuous pulse oximetry and capnography monitoring in high-risk patients.

BD's (BDX) Digital Marketplace Set to Improve User Experience

BD's (BDX) latest online marketplace is expected to offer a better user experience to its flow cytometry users.